Most acute cardiovascular events are attributable to arterial thrombosis. Plaque rupture or erosion stimulates platelet activation, aggregation, and thrombosis, whilst simultaneously activating enzymatic processes that mediate endogenous fibrinolysis to physiologically maintain vessel patency. Interplay between these pathways determines clinical outcome. If proaggregatory factors predominate, the thrombus may propagate, leading to vessel occlusion. However, if balanced by a healthy fibrinolytic system, thrombosis may not occur or cause lasting occlusion. Despite abundant evidence for the fibrinolytic system regulating thrombosis, it has been overlooked compared with platelet reactivity, partly due to a lack of techniques to measure it. We evaluate evidence for endogenous fibrinolysis in arterial thrombosis and review techniques to assess it, including biomarkers and global assays, such as thromboelastography and the Global Thrombosis Test. Global assays, simultaneously assessing proaggregatory and fibrinolytic pathways, could play a role in risk stratification and in identifying impaired fibrinolysis as a potential target for pharmacological modulation. (J Am Coll Cardiol 2015;65:1683-99)
tries. The common pathological process responsible for the majority of these disorders, including acute coronary syndrome (ACS) and ischemic stroke, is the development of an occlusive arterial thrombus.
Disruption of an atherosclerotic plaque through rupture or erosion creates a prothrombotic environment to circulating platelets and procoagulant factors. The major thrombogenic components contained within the atherosclerotic plaque include tissue factor and collagen (1) (2) (3) . Exposure to this thrombotic milieu provides a potent stimulus for platelet activation, aggregation, and thrombosis ( Figures 1A and 1B) .
Activation of the coagulation cascade also leads to direct activation of the enzymatic processes that mediate endogenous fibrinolysis ( Figure 1C ). This interaction is important to ensure that thrombosis is controlled and vessel patency is maintained. trial (11), SR was associated with a lower composite of death, heart failure, or shock compared with those with persistent ST-segment elevation. In 710 STEMI patients undergoing primary percutaneous coronary intervention, SR was observed in 22%, and these patients had a lower incidence of death, congestive heart failure, and recurrent ACS at 30 days than those without SR (12) . Furthermore, histopathologic studies evaluating aspirated coronary thrombi from patients with STEMI have demonstrated significant heterogeneity in the composition and age of the culprit thrombi (4-7). Among 1,362 STEMI patients, up to 40% demonstrated lytic or organized thrombi, signifying that thrombus formation occurred days to weeks before final vessel occlusion (7). This underpins the notion that thrombus generation is an active and dynamic process, where constant thrombosis and thrombolysis may occur in concert.
Autopsy studies of healed plaque disruptions also provide evidence of thrombus formation as a dynamic process (8, 13) . Plaque instability appears to be present for some time before an occlusive thrombus is formed, and may be asymptomatic. Nonocclusive mural thrombi may form over plaque disruptions, leading to phasic progression of atherosclerotic lesions, but without presenting as ACS (13, 14) .
Despite the fact that plaque rupture represents a common unifying event for coronary thrombosis, there is significant variability in clinical manifestation and outcome. This variability may be explained, in part, by the role of endogenous fibrinolysis in limiting the propagation of formed thrombi and preventing total coronary occlusion (Central Illustration).
In this paper, we review the methods currently available to assess endogenous fibrinolysis and evaluate the evidence for the role of endogenous fibrinolysis as a mediator of arterial thrombus formation in coronary disease.
FACTORS DETERMINING RESISTANCE OF THROMBUS TO LYSIS
Whole blood clots are more resistant to lysis than plasma clots, implying that blood cells and fibrin are responsible for the resistance (15) (Central Illustration). Platelets play the main role in resistance, but red cell-derived microparticles can also contribute to thrombin generation, whereas elastase released from leukocytes trapped or adherent to the thrombus exerts a plasmin-independent fibrinolytic effect. Arterial (platelet-rich) thrombi are much more resistant to lysis than erythrocyte-rich venous thrombi (16) . The mechanisms through which platelets contribute to thrombolysis resistance are 3-fold (Central Illustration):
1. Platelets contain >90% of the circulating plasminogen activator inhibitor (PAI)-1. During aggregation, in response to thrombin, PAI-1 is released from platelets into the thrombus mass and is the major determinant of arterial thrombolysis resistance (17).
2. The procoagulant activity or contribution of platelets to thrombin generation is extremely important, not only in the generation of, but also in the lysis of the formed thrombus. A high shear stress milieu, such as that found in an artery with a severe stenosis, will trigger microparticle release from activated platelets, resulting in a burst of thrombin generation. In addition to PAI-1, thrombin-activatable fibrinolysis inhibitor (TAFI) also contributes to thrombolysis resistance. Okafor and Gorog JACC VOL. 65, NO. 16, 2015 Endogenous Thrombolysis in CV Disease A P R I L 2 8 , 2 0 1 5 : 1 6 8 3 -9 9 FIGURE 1 The Mechanism and Importance of Endogenous Fibrinolysis in Regulation of Occlusive Arterial Thrombus Formation, and its Relevance to Laboratory Tests Assessing Thrombotic Risk (A) Under conditions of high shear, such as those that exist in a narrowed coronary artery, stimulation of platelet aggregation by von Willebrand Factor (vWF) results in the formation of thrombin, the key mediator of thrombus formation. (B) The thrombus achieves structural stability and resistance to dislodgement and to thrombolysis through fibrin (which crosslinks cells to provide structural stability), plasminogen activator inhibitor (PAI)-1 released from activated platelets, and activation of thrombinactivatable fibrinolysis inhibitor (TAFI) by thrombin. (C) Endogenous thrombolysis: physiological processes that exist to prevent lasting occlusive thrombus formation, including the release of tissue plasminogen activator (t-PA) and urokinase plasminogen activator (u-PA) from the vessel wall and plasma, the release of elastase and cathepsin from adherent neutrophils and monocytes, and the dispersing effect of flow. ADP ¼ adenosine diphosphate; TxA 2 ¼ thromboxane A 2 .
3. The structure and stability of the resultant fibrin network is also a determinant of thromboresistance (18) . Platelets play an important role in regulating fibrin network structure (19) . Coagulation factor XIII (FXIII), in addition to cross-linking fibrin, also plays an important role in thrombolysis resistance. Platelets are abundant in FXIII, and upon activation, FXIII-A exposure on the surface membrane exerts an antifibrinolytic function by cross-linking the major plasmin inhibitor a2-antiplasmin to fibrin, thus inhibiting plasminmediated clot degradation (20, 21) . FXIII alters the structure of the fibrin network to reduce pore size and increase fiber density, thus increasing clot stability and resistance to lysis (22) . Thrombi formed in FXIII-deficient blood lyse more quickly than in normal blood, and FXIII concentrate normalized lysis (23) . A common genetic polymorphism of FXIII has been shown to increase the risk of myocardial infarction (24) .
MEASUREMENT OF FIBRINOLYTIC STATUS
Interest in the endogenous fibrinolytic system has fueled the development of techniques to assess and quantify the activity of this important pathway. Many Thrombin converts plasminogen to plasmin, which breaks down the cross-linked fibrin into soluble fibrin degradation products. t-PA is mainly responsible for the dissolution of fibrin formed in the circulation. Inhibitors of thrombolysis include the release of PAI-1 from platelets, secretion of active PAI-1 from aggregated platelets, and clot retraction. Potentiators of thrombolysis include: the release of elastase and cathepsin G from white blood cells that become trapped in the thrombus, which directly break down fibrin; the plasminogen activators uPA and t-PA (released from endothelial cells); and fibrin structural properties. The thickness and porosity of fibrin fibers will also determine structural stability and susceptibility to thrombolysis. Lp(a), a homologue of plasminogen, can inhibit t-PA-mediated plasminogen activation. aTAFI ¼ activated thrombin-activatable fibrinolysis inhibitor; CV ¼ cardiovascular; EC ¼ endothelial cell; FXIII ¼ coagulation factor XIII; Lp(a) ¼ lipoprotein (a); PAI-1 ¼ plasminogen activator inhibitor; PAR ¼ protease-activated thrombin receptor; TAFI ¼ thrombin-activatable fibrinolysis inhibitor; t-PA ¼ tissue plasminogen activator.
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PLASMA MARKERS OF FIBRINOLYSIS
The fibrinolytic system shares several similarities with the coagulation cascade, involving a series of proteolytic enzymatic steps that culminate in the conversion of plasminogen to plasmin to achieve fibrin dissolution ( Figure 1C (25, 28, 31) , and, more recently, TAFI (31) and Lp(a) (31, 32) .
Given the potential role of the fibrinolytic system in the pathogenesis of ACS, studies have attempted to elucidate the relationship between plasma biomarkers and incipient cardiovascular risk. The main limitations of this approach are knowing the relative importance and contribution of any biomarker to the overall fibrinolytic system at any given point, knowing whether to measure levels or activity of biomarkers, and the confounding association between fibrinolytic markers and more established cardiovascular risk factors (33, 34) . Overall, the outcome of studies evaluating the role of plasma markers of fibrinolysis as independent predictors of cardiovascular risk has been disappointing, with much conflicting evidence and a number of positive studies only demonstrating a weak association (31) . This, combined with methodological problems with the assays, has resulted in greater emphasis being placed on more global assays of fibrinolytic activity.
EUGLOBULIN CLOT LYSIS TIME
The euglobulin fraction (containing the key activators of the fibrinolytic cascade, including plasminogen activators, plasminogen, and plasmin) is precipitated from citrated plasma and calcium is added to promote clot formation. The time taken to lyse this clot is utilized as a measure of fibrinolytic activity (35, 36) .
This technique from the 1950s has now been superseded by more rapid, physiological tests of fibrinolytic capacity.
THROMBOELASTOGRAPHY
TEG is a global test of coagulation status, simultaneously assessing clot development, stabilization, and dissolution. Another related and commerciallyavailable technique is ROTEM (37, 38) . TEG utilizes a pin suspended by a torsion wire into a cylinder to measure the physical properties of a clot. The torsion wire is connected to a mechanical-electrical transducer and relays information on the speed and 
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A P R I L 2 8 , 2 0 1 5 : 1 6 8 3 -9 9 is typically compared in the presence and absence of the fibrinolysis inhibitor aprotinin (37, 46) . Table 1 shows the features of thromboelastography and how these compare with the GTT.
There There are significant differences in TEG results between fresh native whole blood and recalcified citrated whole blood (49, 50) and the correlation between TEG results performed on kaolin-versus nonkaolinactivated native and citrated blood is poor (51). Okafor and Gorog JACC VOL. 65, NO. 16, 2015 Endogenous Thrombolysis in CV Disease Despite these limitations, TEG benefits from its availability as a point-of-care test, providing rapid information on the coagulation profile of patients.
GLOBAL THROMBOSIS TEST
The GTT is a newer point-of-care test that simultaneously assesses platelet reactivity, thrombosis, and thrombolytic activity, from a single, nonanticoagulated blood sample (56, 57) . This technique utilizes native, nonanticoagulated blood that is free of any external agonists ( Table 1) Tables 1 and 2 .
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In 1 of the larger prospective studies that evaluated t-PA levels in 3,582 women, there was a weak correlation between t-PA and the development of coronary artery disease (25) . In patients with established coronary disease or AMI, t-PA levels were predictive of future cardiovascular events. In the Caerphilly Study of 2,398 men with 13 years of follow-up, baseline PAI-1 levels were significantly associated with cardiovascular risk (64) , but after multivariate analysis, the correlation became nonsignificant (64) . Other studies evaluating PAI-1 demonstrated a significant association with coronary events (65), cardiogenic shock, Tables 2 and 3 .
Okafor and Gorog JACC VOL. 65, NO. 16, 2015 Endogenous Thrombolysis in CV Disease A P R I L 2 8 , 2 0 1 5 : 1 6 8 3 -9 9 death (32), and major adverse cardiovascular events (MACE) (32) . In the Framingham study involving 3,209 participants, PAI-1 levels were not related to cardiovascular events (66) . Other studies have also failed to demonstrate a prognostic role for baseline t-PA or PAI-1 levels (27, 28) . There is also conflicting data from studies on the role of other plasma markers of fibrinolysis, including D-dimer assays (25, 28, 31, 64) , plasmin-alpha2-antiplasmin complex measurements (31), TAFI (31) , and Lp(a) levels (31, 32) . Clinical studies evaluating the GTT are shown in Table 3 . A study of 300 patients with ACS (61) revealed that although platelet reactivity was (Table 4) .
However, TEG has proven to be a less robust measure of hypofibrinolysis, with unmodified TEG assays in normal subjects exhibiting only a minor degree of fibrinolysis. Indeed, in 1 study, the normal range of ROTEM maximum lysis at 60 min was demonstrated to be <12% (range 0% to 12%) (89 Table 4) .
CONCLUSIONS
Although previously viewed as a secondary phenomenon in response to the formation of thrombi, a large body of evidence now points to a much more prominent role for endogenous fibrinolysis in thrombus formation.
The technical limitations, difficulty in interpretation, and conflicting data regarding prognostic usefulness of plasma markers in patients with coronary disease limit their adoption into clinical practice.
Recognition of these limitations prompted the development of global assays of fibrinolytic status. TEG is a useful tool for assessing bleeding risk, and has also been used to assess clot strength, which has been shown to predict future cardiovascular events.
However, its practical value in assessing the (spontaneous) thrombolytic status of patients or the effect of medications is questionable, due to its inability to assess the procoagulant and fibrinolysis-inhibiting 
